I

Instil Bio Inc
NASDAQ:TIL

Watchlist Manager
Instil Bio Inc
NASDAQ:TIL
Watchlist
Price: 11.27 USD 1.58% Market Closed
Market Cap: 76.4m USD

Instil Bio Inc
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Instil Bio Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
I
Instil Bio Inc
NASDAQ:TIL
Income from Continuing Operations
-$74m
CAGR 3-Years
22%
CAGR 5-Years
-63%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$2.4B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$8.1B
CAGR 3-Years
35%
CAGR 5-Years
46%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

Instil Bio Inc
Glance View

Market Cap
76.4m USD
Industry
Biotechnology

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 412 full-time employees. The company went IPO on 2021-03-19. The firm is focused on developing a cell therapy pipeline of autologous tumor-infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. TIL therapies leverage platform for TIL manufacturing has been designed for the scalability, logistics, and accessibility of TIL therapy. The company is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. The company is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. ITIL-168 is an autologous TIL therapy that it is initially developed for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its CoStAR-TIL product candidate.

TIL Intrinsic Value
4.3 USD
Overvaluation 62%
Intrinsic Value
Price
I

See Also

What is Instil Bio Inc's Income from Continuing Operations?
Income from Continuing Operations
-74m USD

Based on the financial report for Dec 31, 2024, Instil Bio Inc's Income from Continuing Operations amounts to -74m USD.

What is Instil Bio Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-63%

Over the last year, the Income from Continuing Operations growth was 53%. The average annual Income from Continuing Operations growth rates for Instil Bio Inc have been 22% over the past three years , -63% over the past five years .

Back to Top